financetom
Business
financetom
/
Business
/
Vicor Insider Sold Shares Worth $8,212,935, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vicor Insider Sold Shares Worth $8,212,935, According to a Recent SEC Filing
Mar 11, 2026 11:18 AM

01:52 PM EDT, 03/11/2026 (MT Newswires) -- Patrizio Vinciarelli, 10% Owner, Director, Chairman and CEO, on March 09, 2026, sold 50,000 shares in Vicor ( VICR ) for $8,212,935. Following the Form 4 filing with the SEC, Vinciarelli has control over a total of 9,679,288 common shares of the company, with 9,508,163 shares held directly and 171,125 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/751978/000119312526101748/xslF345X05/ownership.xml

Price: 177.49, Change: +1.69, Percent Change: +0.96

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US clothing retailers test full-price strategy as rich shoppers keep spending
US clothing retailers test full-price strategy as rich shoppers keep spending
Sep 5, 2025
NEW YORK (Reuters) -A handful of apparel retailers including Levi's and Aritzia are teasing more full-priced products, testing how much wealthier shoppers are willing to pay despite the sobering effect of tariffs. They have not been disappointed so far. Levi Strauss, for instance, raised prices on some products in July but saw no slowdown in demand, the denim maker's chief financial...
BioNTech's Breast Cancer Drug Meets Primary Endpoint in Phase 3 Interim Analysis
BioNTech's Breast Cancer Drug Meets Primary Endpoint in Phase 3 Interim Analysis
Sep 5, 2025
06:01 AM EDT, 09/05/2025 (MT Newswires) -- BioNTech (BNTX) and China's Duality Biologics said Friday that their phase 3 trial evaluating trastuzumab pamirtecan in patients with a certain type of breast cancer met its primary endpoint in an interim analysis. A joint statement said the study, which compared BioNTech's trastuzumab pamirtecan drug candidate with Roche's approved antibody drug-conjugate trastuzumab emtansine,...
Update: Lululemon Fiscal Q2 Earnings Fall, Revenue Rises; Full-Year Outlook Cut -- Shares Down Pre-Bell
Update: Lululemon Fiscal Q2 Earnings Fall, Revenue Rises; Full-Year Outlook Cut -- Shares Down Pre-Bell
Sep 5, 2025
05:46 AM EDT, 09/05/2025 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.) Lululemon Athletica ( LULU ) shares were down 18% in recent premarket activity Friday after the company overnight lowered its full-year financial outlook. The company reported fiscal Q2 net income late Thursday of $3.10 per diluted share, down from...
BRIEF-Lafayette Acquisition Corp Files For IPO Of Up To $100 Mln -SEC Filing
BRIEF-Lafayette Acquisition Corp Files For IPO Of Up To $100 Mln -SEC Filing
Sep 5, 2025
Sept 5 (Reuters) - Lafayette Acquisition Corp: * LAFAYETTE ACQUISITION CORP FILES FOR IPO OF UP TO $100 MILLION - SEC FILING * LAFAYETTE ACQUISITION CORP: TO LIST UNITS ON THE NASDAQ STOCK MARKET LLC UNDER THE SYMBOL LAFAU * LAFAYETTE ACQUISITION CORP: EARLYBIRDCAPITAL, INC IS UNDERWRITER TO IPO - SEC FILING Source text: ;)) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved